14.72
price up icon3.59%   0.51
after-market アフターアワーズ: 14.70 -0.02 -0.14%
loading
前日終値:
$14.21
開ける:
$14.01
24時間の取引高:
11.49M
Relative Volume:
0.87
時価総額:
$6.67B
収益:
$285.55M
当期純損益:
$-353.86M
株価収益率:
-15.49
EPS:
-0.9501
ネットキャッシュフロー:
$-305.02M
1週間 パフォーマンス:
+10.59%
1か月 パフォーマンス:
+57.26%
6か月 パフォーマンス:
+285.34%
1年 パフォーマンス:
+557.14%
1日の値動き範囲:
Value
$13.80
$14.74
1週間の範囲:
Value
$13.29
$14.94
52週間の値動き範囲:
Value
$1.76
$15.30

Iovance Biotherapeutics Inc Stock (IOVA) Company Profile

Name
名前
Iovance Biotherapeutics Inc
Name
セクター
Healthcare (1051)
Name
電話
(650) 260-7120
Name
住所
825 INDUSTRIAL ROAD, SAN CARLOS
Name
職員
975
Name
Twitter
Name
次回の収益日
2026-11-05
Name
最新のSEC提出書
Name
IOVA's Discussions on Twitter

Compare IOVA vs VRTX, MRNA, REGN, ARGX, ONC

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
IOVA icon
IOVA
Iovance Biotherapeutics Inc
14.72 6.67B 285.55M -353.86M -305.02M -0.9501
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
508.75 128.95B 12.34B 4.34B 3.71B 16.87
MRNA icon
MRNA
Moderna Inc
236.50 94.42B 2.23B -3.19B -1.60B -8.1462
REGN icon
REGN
Regeneron Pharmaceuticals Inc
796.34 81.99B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
846.27 53.22B 4.16B 1.29B 734.26M 19.58
ONC icon
ONC
Beone Medicines Ltd Adr
374.08 42.32B 5.76B 514.49M 1.10B 4.4813

Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-09-24 再開されました Goldman Buy
2026-02-25 アップグレード Citizens Mkt Perform → Mkt Outperform
2025-07-15 ダウングレード Goldman Neutral → Sell
2025-05-16 ダウングレード UBS Buy → Neutral
2025-05-12 ダウングレード Truist Buy → Hold
2025-05-09 ダウングレード Citizens JMP Mkt Outperform → Mkt Perform
2024-10-24 開始されました UBS Buy
2024-07-29 ダウングレード Piper Sandler Overweight → Neutral
2023-11-20 開始されました Goldman Buy
2023-09-18 繰り返されました Barclays Overweight
2023-05-30 アップグレード Wells Fargo Equal Weight → Overweight
2023-03-27 再開されました Wells Fargo Equal Weight
2023-01-27 アップグレード Piper Sandler Neutral → Overweight
2022-12-09 ダウングレード Goldman Buy → Neutral
2022-10-31 開始されました Guggenheim Neutral
2022-08-18 再開されました Wells Fargo Equal Weight
2022-01-28 アップグレード Stifel Hold → Buy
2021-12-07 再開されました Cowen Outperform
2021-06-10 アップグレード JMP Securities Mkt Perform → Mkt Outperform
2021-05-20 ダウングレード Piper Sandler Overweight → Neutral
2021-05-19 ダウングレード JMP Securities Mkt Outperform → Mkt Perform
2021-05-19 ダウングレード Stifel Buy → Hold
2021-05-03 開始されました Truist Buy
2021-04-16 開始されました Goldman Buy
2021-03-08 アップグレード H.C. Wainwright Neutral → Buy
2020-12-15 ダウングレード H.C. Wainwright Buy → Neutral
2020-10-06 ダウングレード Wells Fargo Overweight → Equal Weight
2020-04-22 開始されました Mizuho Buy
2020-03-04 開始されました Barclays Overweight
2020-02-26 繰り返されました H.C. Wainwright Buy
2020-02-26 繰り返されました Oppenheimer Outperform
2019-12-18 開始されました JMP Securities Mkt Outperform
2019-10-01 開始されました Stifel Buy
2019-04-29 開始されました Piper Jaffray Overweight
2019-02-28 繰り返されました Chardan Capital Markets Buy
2019-02-07 開始されました Robert W. Baird Outperform
2018-12-31 再開されました B. Riley FBR Buy
2018-07-06 繰り返されました Chardan Capital Markets Buy
2018-04-10 アップグレード B. Riley FBR, Inc. Neutral → Buy
2018-03-13 繰り返されました B. Riley FBR, Inc. Neutral
2018-02-23 ダウングレード B. Riley FBR, Inc. Buy → Neutral
2018-01-25 繰り返されました H.C. Wainwright Buy
2017-11-01 繰り返されました B. Riley FBR, Inc. Buy
すべてを表示

Iovance Biotherapeutics Inc (IOVA) 最新ニュース

pulisher
Oct 09, 2026

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings - Zacks Investment Research

Oct 09, 2026
pulisher
Oct 04, 2026

Iovance Biotherapeutics, Inc. (IOVA) Stock Price, News, Quote & History - Yahoo! Finance Canada

Oct 04, 2026
pulisher
Oct 02, 2026

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar - Zacks Investment Research

Oct 02, 2026
pulisher
Oct 02, 2026

Iovance Biotherapeutics (LSE:0JDK) Stock Forecast & Analyst Predictions - Simply Wall Street

Oct 02, 2026
pulisher
Oct 01, 2026

Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer - The Manila Times

Oct 01, 2026
pulisher
Oct 01, 2026

Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer - GlobeNewswire Inc.

Oct 01, 2026
pulisher
Oct 01, 2026

Iovance's new medical chief led programs that helped drive a drug above $2 billion in annual sales. - Stock Titan

Oct 01, 2026
pulisher
Sep 30, 2026

IOVA Stock Hits 52-Week High on Raised Revenue Outlook for 2026 - Zacks Investment Research

Sep 30, 2026
pulisher
Sep 30, 2026

Iovance Biotherapeutics (IOVA) Surges 31.5%: Is This an Indication of Further Gains? - Zacks Investment Research

Sep 30, 2026
pulisher
Sep 30, 2026

Iovance Biotherapeutics (NasdaqGM:IOVA) Stock Forecast & Analyst Predictions - Simply Wall Street

Sep 30, 2026
pulisher
Sep 21, 2026

Biotech ETFs to Buy as Cancer Drug Breakthroughs Accelerate - Zacks Investment Research

Sep 21, 2026
pulisher
Sep 18, 2026

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire

Sep 18, 2026
pulisher
Sep 18, 2026

Iovance Biotherapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Moomoo

Sep 18, 2026
pulisher
Sep 10, 2026

Iovance Biotherapeutics' Chief Regulatory Officer Reports RSU Vesting and Tax Withholding Transactions - Kalkine Media

Sep 10, 2026
pulisher
Sep 10, 2026

Iovance at Wells Fargo conference: sales momentum lifts outlook By Investing.com - Investing.com Australia

Sep 10, 2026
pulisher
Sep 10, 2026

Iovance at Wells Fargo conference: sales momentum lifts outlook By Investing.com - Investing.com UK

Sep 10, 2026
pulisher
Sep 09, 2026

Iovance Biotherapeutics (IOVA) Institutional Ownership 2026 - MarketBeat

Sep 09, 2026
pulisher
Sep 08, 2026

Why Did IOVA, AMLX And COP Stocks Surge To 52-Week Highs Today? - Stocktwits

Sep 08, 2026
pulisher
Sep 06, 2026

How Iovance Biotherapeutics Inc. (IOVA) Affects Rotational Strategy Timing - Stock Traders Daily

Sep 06, 2026
pulisher
Sep 04, 2026

Iovance Biotherapeutics, Inc. (IOVA) Latest Press Releases & Corporate News - Yahoo Finance

Sep 04, 2026
pulisher
Sep 04, 2026

Iovance Biotherapeutics to Present at Upcoming Conferences - GlobeNewswire

Sep 04, 2026
pulisher
Sep 03, 2026

NFLX: Netflix Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits

Sep 03, 2026
pulisher
Sep 01, 2026

Iovance Biotherapeutics (IOVA) Stands Out with Strong Quant Rati - GuruFocus

Sep 01, 2026
pulisher
Aug 29, 2026

Iovance Biotherapeutics (IOVA) Wins FDA Trial Clearance, Is The Stock Still 54% Undervalued? - sahmcapital.com

Aug 29, 2026
pulisher
Aug 27, 2026

Iovance Biotherapeutics Inc. (IOVA) Peer Comparison – Compare with Others - Value Research

Aug 27, 2026
pulisher
Aug 27, 2026

Zacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and Precigen - Eastern Progress

Aug 27, 2026
pulisher
Aug 22, 2026

Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Tops Revenue Estimates - Eastern Progress

Aug 22, 2026
pulisher
Aug 21, 2026

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - The Manila Times

Aug 21, 2026
pulisher
Aug 21, 2026

Biotech company Iovance grants 20 new employees options with an $8.99 exercise price - Stock Titan

Aug 21, 2026
pulisher
Aug 21, 2026

Iovance Biotherapeutics (NASDAQ:IOVA) Stock Price Down 5.8%Here's Why - MarketBeat

Aug 21, 2026
pulisher
Aug 21, 2026

IOVA Stock Pulls Back As Biotech Momentum Cools - StocksToTrade

Aug 21, 2026
pulisher
Aug 21, 2026

UBS Lifts Iovance Biotherapeutics Price Target as Cancer Drug Sales Top Expectations - TIKR.com

Aug 21, 2026
pulisher
Aug 21, 2026

Iovance Biotherapeutics Stock Is Trending Friday: What's Going On? - Benzinga

Aug 21, 2026
pulisher
Aug 20, 2026

Why Did IOVA, AMLX And COP Stocks Surge To 52-Week Highs Today? - TradingView

Aug 20, 2026
pulisher
Aug 20, 2026

Iovance Biotherapeutics grants inducement stock options to 27 new employees - scanx.trade

Aug 20, 2026
pulisher
Aug 20, 2026

IOVA Stock Hits Fresh 52-Week Peak On UBS Target Hike, Melanoma Sector Optimism - Yahoo Finance

Aug 20, 2026
pulisher
Aug 20, 2026

Iovance Shares Rise 12.5% as Analyst Price Targets Lag Behind Rally - TechStock²

Aug 20, 2026
pulisher
Aug 20, 2026

IOVA Stock Hits Fresh 52-Week Peak On UBS Target Hike, Melanoma Sector Optimism - Stocktwits

Aug 20, 2026
pulisher
Aug 20, 2026

Iovance Biotherapeutics stock trends on sector momentum, Q2 beat - scanx.trade

Aug 20, 2026
pulisher
Aug 20, 2026

Why Iovance Biotherapeutics Stock Hit 52-Week High - TradingView

Aug 20, 2026
pulisher
Aug 20, 2026

IOVA Maintained by UBS -- Price Target Raised to $7.00 - GuruFocus

Aug 20, 2026
pulisher
Aug 20, 2026

Iovance's Growth Outlook Clouded as Amtagvi Faces Competition Hurdles, UBS Says - marketscreener.com

Aug 20, 2026
pulisher
Aug 20, 2026

META_TITLE_QUOTE - Yahoo Finance

Aug 20, 2026
pulisher
Aug 20, 2026

IOVA Stock Climbs As Earnings Beat Fuels Guidance Rethink - StocksToTrade

Aug 20, 2026
pulisher
Aug 20, 2026

Iovance Biotherapeutics (NASDAQ:IOVA) Marks Major Market Shift - Kalkine Media

Aug 20, 2026
pulisher
Aug 20, 2026

Here's Why Iovance Biotherapeutics (IOVA) is a Great Momentum Stock to Buy - Yahoo Finance

Aug 20, 2026
pulisher
Aug 20, 2026

Iovance Biotherapeutics: Breakout Quarter, Catalysts Ahead, And Competitor Updates (IOVA) - Seeking Alpha

Aug 20, 2026
pulisher
Aug 20, 2026

UBS raises Iovance Biotherapeutics stock price target on revenue beat By Investing.com - Investing.com Canada

Aug 20, 2026
pulisher
Aug 20, 2026

Iovance Biotherapeutics (NASDAQ:IOVA) Reaches New 12-Month HighWhat's Next? - MarketBeat

Aug 20, 2026
pulisher
Aug 20, 2026

IOVANCE BIOTHERAPEUTICS INC : UBS RAISES TARGET PRICE TO $7 FROM $4 - webull.com

Aug 20, 2026

Iovance Biotherapeutics Inc (IOVA) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Iovance Biotherapeutics Inc (IOVA) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
BILINSKY IGOR
Chief Operating Officer
Sep 08 '26
Option Exercise
0.00
7,813
0
146,050
Puri Raj K.
Chief Regulatory Officer
Sep 08 '26
Option Exercise
0.00
9,766
0
260,842
Vogt Frederick G
Interim CEO & General Counsel
Sep 01 '26
Option Exercise
0.00
41,669
0
604,161
Puri Raj K.
Chief Regulatory Officer
Sep 01 '26
Option Exercise
0.00
5,470
0
253,584
BILINSKY IGOR
Chief Operating Officer
Sep 01 '26
Option Exercise
0.00
8,789
0
142,709
Kirby Daniel Gordon
Chief Commercial Officer
Aug 10 '26
Option Exercise
0.00
10,001
0
156,947
Roche Corleen M.
Chief Financial Officer
Aug 06 '26
Option Exercise
0.00
49,995
0
49,995
Vogt Frederick G
Interim CEO & General Counsel
Jun 05 '26
Option Exercise
0.00
15,625
0
569,130
GRAF FINCKENSTEIN FRIEDRICH
Chief Medical Officer
Jun 05 '26
Option Exercise
0.00
7,813
0
144,087
Puri Raj K.
Chief Regulatory Officer
Jun 05 '26
Option Exercise
0.00
9,766
0
251,957
$248.24
price up icon 3.86%
$152.62
price down icon 0.07%
$87.97
price up icon 1.45%
$44.12
price up icon 3.33%
$298.50
price up icon 1.19%
$80.10
price up icon 1.87%
大文字化:     |  ボリューム (24 時間):